Sunday, February 25, 2018 5:10:29 AM
CAR-T-Meso
Metastatic Pancreatic (Ductal) Adenocarcinoma
Epithelial Ovarian Cancer
Malignant Epithelial Pleural Mesothelioma
HTTPS://clinicaltrials.gov/ct2/show/NCT02159716
Even more to come
The latest exciting developments with CAR-T are still ringing in the ears of the industry and the good news is expected to keep coming. Novartis is far from done, with a slew of plans ready to unfold in the space, as Althoff outlined: “We are excited about the possibility of CAR-Ts to transform cancer care. Kymriah is just the first of Novartis' CAR-T cell therapies. The company also plans to file Kymriah with the FDA in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), as well as file applications with the European Medicines Agency for both B-cell ALL and DLBCL by the end of this year.
“As part of the company’ ongoing research and development collaboration with Penn, together we’ve generated CTL119 – a humanised anti-CD19 CAR – which is in initial clinical development for multiple B-cell malignancies,” he continued. “We’re also studying CART-BCMA, a novel, fully human CAR targeting BCMA, in multiple myeloma and CD123 CAR-T in myeloid leukaemia. Additionally we are studying a number of other CAR therapies in solid tumours, including a humanised anti-EGFRvIII CAR for Glioblastoma Multiforme, a lethal and common brain cancer, and a fully human anti-Mesothelin CAR (huCART-Meso) which recently began clinical testing.”
CAR-T Type Cancer indication Phase 1 Phase 2/ pivotal Phase 3 Submitted Approved
CD19 CAR-T Pediatric & young adult r/r ALL1 EU US
CD19 CAR-T r/r DLBCL2 US/EU
CD19 CAR-T DLBCL in 1st relapse2 Starting 2018
CD19 CAR-T r/r FL3 Starting 2018
CD19 CAR-T r/r DLBCL2
in combination
with pembrolizumab Starting 2018
CD19 CAR-T CLL4 Starting 2018
CAR-T-BCMA r/r Multiple Myeloma Starting 2018
CAR-T-EGFRvIII Recurrent GBM5 Started
CAR-T-Meso Advanced ovarian cancer,
Mesothelioma Started
Novartis has one of the most comprehensive CAR-T
development programs across multiple large indications
1. ALL – acute lymphoblastic leukemia 2. DLBCL – diffuse large B-cell lymphoma
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM